Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3169172 | 1.00 | ALDH1A1 (0.47) | ALDH1A1 | |
| SCHEMBL3169167 | 1.00 | ALDH1A1 (0.47) | ALDH1A1 | |
| SCHEMBL21339438 | 1.00 | ALDH1A1 (0.47) | ALDH1A1 | |
| SCHEMBL30522338 | 0.97 | ALDH1A1 (0.44) | ALDH1A1 | |
| SCHEMBL21841419 | 0.97 | ALDH1A1 (0.44) | ALDH1A1 | |
| SCHEMBL30223408 | 0.97 | ALDH1A1 (0.44) | ALDH1A1 | |
| SCHEMBL4245681 | 0.94 | — | — | |
| SCHEMBL18731783 | 0.89 | ALDH1A1 (0.35) | ALDH1A1 | |
| SCHEMBL10801830 | 0.88 | — | — | |
| SCHEMBL21829879 | 0.88 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122029177-A | Oligonucleotides containing multiple ligands and/or lipids | 阿达尔克斯制药有限公司 | 2026-05-12 | — | — | CN | disclosed |
| CN-122029176-A | Containing a plurality of oligonucleotides modified oligonucleotides | 阿达尔克斯制药有限公司 | 2026-05-12 | — | — | CN | disclosed |
| CN-122028913-A | Oligonucleotides containing ligands in nucleobases, 2 'or 3' positions | 阿达尔克斯制药有限公司 | 2026-05-12 | — | — | CN | disclosed |
| CN-119110803-A | Novel bicyclic substituted sulfonylurea compounds as inhibitors of interleukin-1 activity | 唯久生物技术(苏州)有限公司 | 2024-12-10 | — | — | CN | disclosed |
| CN-118251393-A | Novel substituted sulfonylurea compounds as inhibitors of interleukin-1 activity | 唯久生物技术(苏州)有限公司 | 2024-06-25 | — | — | CN | disclosed |
| US-20240199602-A1 | INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-06-20 | — | — | US | disclosed |
| CN-117751114-A | Small molecule modulators of glucocerebrosidase activity and uses thereof | 凡况生化公司 | 2024-03-22 | — | — | CN | disclosed |
| US-11905285-B2 | Inhibitors of plasma kallikrein and uses thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-02-20 | — | — | US | disclosed |
| CN-111566113-B | Macrocyclic compounds and uses thereof | 哈佛大学的校长及成员们 | 2024-01-09 | — | — | CN | disclosed |
| US-11777142-B2 | Gelable system containing ether compounds, preparation method therefor and use thereof | BEIJING NORMAL UNIVERSITY (CN) | 2023-10-03 | — | — | US | disclosed |
| US-20060099270-A1 | Production of small particles | APPLIED NANOSYSTEMS B.V. (NL) | 2006-05-11 | — | — | US | disclosed |
| EP-1631261-A2 | PRODUCTION OF SMALL PARTICLES | Applied NanoSystems B.V. (NL) | 2006-03-08 | — | — | EP | disclosed |
| US-20050250857-A1 | Gelling agents | NANO FIBER MATRICES B.V. (NL) | 2005-11-10 | — | — | US | disclosed |
| WO-2005047231-A1 | NON-SYMMETRICAL GELLING AGENT | APPLIED NANOSYSTEMS B.V. (NL) | 2005-05-26 | — | — | WO | disclosed |
| EP-1506168-A2 | GELLING AGENTS | Applied NanoSystems B.V. (NL) | 2005-02-16 | — | — | EP | disclosed |
| WO-2004103347-A2 | PRODUCTION OF SMALL PARTICLES | APPLIED NANOSYSTEMS B.V. (NL) | 2004-12-02 | — | — | WO | disclosed |
| WO-2003097587-A2 | GELLING AGENTS | APPLIED NANOSYSTEMS B.V. (NL) | 2003-11-27 | — | — | WO | disclosed |
| EP-1364941-A1 | Gelling agents | Applied NanoSystems B.V. (NL) | 2003-11-26 | — | — | EP | disclosed |
| US-4515720-A | Method of synthesizing a late-stage intermediate to 11-deoxydaunorubicin and 11-deoxyadriamycin, and two precursors to the object intermediate | OREGON GRADUATE CENTER FOR STUDY & RESEARCH (US) | 1985-05-07 | — | — | US | disclosed |
| EP-0034015-A2 | Pharmaceutically active compounds | BEECHAM GROUP PLC (GB) | 1981-08-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240199602-A1 | INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF | KLKB1, KLK1, KLK5 | ALDH1A1 3858/4885 |
| US-11905285-B2 | Inhibitors of plasma kallikrein and uses thereof | KLKB1, KLK1, KLK5 | ALDH1A1 3858/4885 |
| US-20060099270-A1 | Production of small particles | NPC1L1, FDFT1, PGA5 | ALDH1A1 3916/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.